ALVR AlloVir

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET.

A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at .

About AlloVir

AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company's innovative and proprietary technology platform leverages off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir's technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio. For more information, visit or follow us on or .

EN
16/11/2023

Underlying

ALVRAlloVir

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlloVir

 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir Provides Updates on Phase 3 Clinical Development Program for P...

AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified Company to prioritize capital preservation and review strategic options AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023 WALTHAM, Mass., Dec. ...

December 22, 2023 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir to Present at the Piper Sandler 35th Annual Healthcare Confere...

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City, NY on Tuesday, November 28, 2023 at 10:00 a.m. ET. A live webcast and archived replay of the presentation will be available on the Investors & Press section of the AlloVir website at . About AlloVir AlloVir is a leading late-clinical stage cell therapy company focused on restoring natural ...

November 16, 2023 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir Reports Third Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the third quarter ended September 30, 2023. AlloVir continues to progress its highly innovative lead therapeutic candidate, posoleucel, by enrolling globally in three Phase 3 trials for first-to-market indications. AlloVir is in a position of strength with significant financial resources to support operations through topline data readouts for all three trials anticipated in the second half of 2024. “At AlloVir, we are dedicated t...

November 2, 2023 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET H.C. Wainwright 25th Annual Global Investment Conference Presentation: Tuesday, September 12, 2023 at 12:00 pm ET A live webcast and archived replay of these presentations will be available on the Investors & Press section...

August 28, 2023 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

AlloVir Reports Second Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today reported financial results from the second quarter ended June 30, 2023. The company shared progress across its allogeneic, off-the-shelf virus-specific T cell (VST) programs, including its lead investigational therapy, posoleucel, for prevention and treatment of life-threatening infections and diseases from up to six viruses that commonly impact patients following allogeneic hematopoietic cell transplant (allo-HCT), and for the treatment of BK viremia (BKV) in ad...

August 3, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch